Genmab — September 2020
-
Det er blot en kortsigtet teknisk analyse: https://www.proinvestor.com/investornyt/666637/genmab-begynder-at-vise-svaghedstegn
-
Enhver har kunnet se denne udvikling i den seneste tid.
-
Vor
egen tekniske analyse er her: https://www.proinvestor.com/boards/86703/Teknisk-analyse-af-Genmab -
God morgen.
-
Se svar i Twittertråden og følg den løbende: Vincent Rajkumar @VincentRK Question for hem/onc docs: Newly Diagnosed AL Amyloidosis not in VGPR following frontline ASCT (No induction was given before ASCT). What’s your regimen of choice?https://twitter.com/VincentRK/status/1304414797325312001
-
God morgen.
-
Test
-
God morgen.
-
Vincent Rajkumar
@VincentRK
·
2 t
4 key slides from my talk on “How I Treat Newly Diagnosed Myeloma” athttps://twitter.com/VincentRK/status/1305339743228616704 -
-
-
Vi skal først have overstået alt det med med coronavirus og dens senfølger på økonomien.
-
Janssen to Present Key Data from Across Its Expansive Oncology Portfolio at ESMO 2020 Virtual Congress -
Safety and efficacy data from the Phase 1 CHRYSALIS study exploring amivantamab in combination with lazertinib in patients with advanced EGFR-mutated NSCLC https://www.businesswire.com/news/home/20200913005090/en/Janssen-to-Present-Key-Data-from-Across-Its-Expansive-Oncology-Portfolio-at-ESMO-2020-Virtual-Congress -
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind